Finally, we are convinced that OATD-02 is the only preclinical candidate capable of addressing the beneficial inhibition of cellular ARG2 that regulates the activity of CD8+ cells and Tregs, and constitutes one of the key components of metabolic adaptations of hypoxic tumours along with desired ARG1 inhibition within the TME. The gene discussed is CD8A; the disease is neoplasm.